Characteristics of Mucormycosis in Hematological Patients and a Death Prediction Model

Mucormycosis is an angioinvasive fungal infection, associated with high mortality. The aim of our study was to explore the high-risk factors and predict the death of hematological disease complicated with mucormycosis. We retrospectively analyzed clinical data of 31 patients with hematological disease complicated with mucormycosis, adopted random forest to establish the death prediction model, and validated the model in another 15 patients. The median age of the 31 cases was 46 (28–51) years, male to female ratio 1.38:1, and 90-day mortality rate 54.8%. The most common underlying disease was acute myeloid leukemia (58.1%). The main clinical symptoms were fever (100%), cough (87.1%), sputum (80.6%), chest pain (61.3%), and hemoptysis (19.4%). Reversed halo sign (83.9%) was the most common computed tomography sign. A total of 48.4% of patients also had aspergillus or bacterial infections. Discriminative models were constructed by random forest with 17 non-survivors and 14 survivors. Procalcitonin, the duration of intravenous administration of amphotericin B or amphotericin B liposomes, and neutropenia at death or 90 days of survival were the leading risk factors for poor prognosis, with area under the curve of 0.975 (95% CI 0.934–1). We chose 0.6775 as death prediction threshold (with 82.3% sensitivity and 100% specificity) and validated the model successfully in another 15 patients. Chest pain and reversed halo sign are specific clinical and image signs of hematological disease complicated with mucormycosis. Neutropenia, elevated procalcitonin, and insufficient use time of amphotericin B or amphotericin B liposomes are risk factors for death.

[1]  É. Azoulay,et al.  Poor outcome associated with mucormycosis in critically ill hematological patients: results of a multicenter study , 2021, Annals of Intensive Care.

[2]  A. Chakrabarti,et al.  Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis. , 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  Jing Yang,et al.  Deciphering the Relationship Between the Trough Concentration of Posaconazole and Its Efficacy and Safety in Chinese Patients With Hematological Disorders , 2020, Frontiers in Pharmacology.

[4]  C. Schwebel,et al.  Mucormycosis in intensive care unit: surgery is a major prognostic factor in patients with hematological malignancy , 2020, Annals of Intensive Care.

[5]  E. Hart,et al.  Pulmonary Mucormycosis: Risk Factors, Radiologic Findings, and Pathologic Correlation. , 2020, Radiographics : a review publication of the Radiological Society of North America, Inc.

[6]  H. Badali,et al.  Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. , 2019, The Lancet. Infectious diseases.

[7]  R. Wolfe,et al.  Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports. , 2019, International journal of antimicrobial agents.

[8]  A. Chakrabarti,et al.  Global Epidemiology of Mucormycosis , 2019, Journal of fungi.

[9]  B. Afanasyev,et al.  Contrasts between mucormycosis and aspergillosis in oncohematological patients. , 2019, Medical mycology.

[10]  Hojoong Kim,et al.  Factors affecting surgical resection and treatment outcomes in patients with pulmonary mucormycosis. , 2019, Journal of thoracic disease.

[11]  R. Wolfe,et al.  The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  Xuefeng Sun,et al.  Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome , 2018, Infection.

[13]  A. Limper,et al.  Pulmonary mucormycosis: clinical features and outcomes , 2017, Infection.

[14]  D. Marriott,et al.  Mucormycosis in Australia: contemporary epidemiology and outcomes. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  D. Kontoyiannis,et al.  Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  Kyoung Hwa Lee,et al.  Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis , 2015, Mycoses.

[17]  C. Elie,et al.  Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. , 2015, Journal of Antimicrobial Chemotherapy.

[18]  Yonggoo Kim,et al.  Determination of posaconazole concentration with LC-MS/MS in adult patients with hematologic malignancy. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[19]  Sung‐Han Kim,et al.  Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  P. Pagès,et al.  The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  D. Kontoyiannis,et al.  Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis , 2014, Mycoses.

[22]  C. Elie,et al.  A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  D. Kontoyiannis,et al.  Epidemiology and clinical manifestations of mucormycosis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Marit D. Moen,et al.  Liposomal Amphotericin B , 2012, Drugs.

[25]  P. Hamal,et al.  Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[26]  Y. Taşova,et al.  Mucormycosis‐associated fungal infections in patients with haematologic malignancies , 2009, International journal of clinical practice.

[27]  D. Kontoyiannis,et al.  Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. Kontoyiannis,et al.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  G. Carrafiello,et al.  Mucormycosis in hematologic malignancies: an emerging fungal infection. , 2000, Haematologica.

[30]  J. Lowe,et al.  Pulmonary mucormycosis: results of medical and surgical therapy. , 1994, The Annals of thoracic surgery.